Clinical trials: Virus
Herpes Zoster
Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A in Adults With a Prior Episode of Herpes Zoster
The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' HZ/su vaccine in subjects' ≥ 50 years of age (YOA) who previously have had Herpes Zoster (HZ).
- Trial name
- NCT01827839
- Testing
- Herpes Zoster vaccine (GSK1437173A)
- Where
- 4 sites in Canada, Russia
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Covid19
COVID-19 Saliva Test Research Study
The objective of this study is to compare the Chronomics test against the NPS tests and protocol currently in use to demonstrate the efficacy of Chronomics' approach.
- Trial name
- NCT04531501
- Testing
- Saliva and NPS test
- Where
- 2 sites in United Kingdom
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Chronomics Limited
Respiratory Syncytial Virus Infections
RSV-MVA-BN Vaccine Phase I Trial, Intranasal Application in Adults.
A total of 96 subjects will be recruited into 5 groups. Each subject will receive either two vaccinations with MVA-BN-RSV vaccine or placebo.
- Trial name
- NCT02864628
- Testing
- MVA-BN-RSV
- Volunteers
- healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Non-Hodgkin Lymphoma (NHL)
Response to Influenza Vaccination in Lymphoma Patients Treated With Rituximab
The purpose of this study is to compare the number of responders to vaccination with the influenza virus vaccine at different time points after last dose of rituximab in patients with lymphoma.
- Trial name
- Rituxivac (NCT01707628)
- Testing
- influenza vaccination with influenza vaccine
- Where
- 7 sites in Netherlands
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- St. Antonius Hospital
Human Immunodeficiency Virus, Tuberculosis
Usability Study of IeHS in Indonesia
Technology that has a particular focus on patients' needs and ease-of-use and -access plays a significant role in the development of e-health and m-health.
- Conditions
- Human Immunodeficiency Virus, Tuberculosis, Interpersonal Relations, Mobile Phone Use
- Trial name
- NCT04179344
- Testing
- Integrated e-healthcare services (IeHS) web-based app
- Where
- 3 sites in Indonesia
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Bekasi City Public Hospital
Substance Abuse, Intimate Partner Violence (IPV)
SER Familia: A Family-Based Intervention Addressing Syndemic Conditions Among Latino Families
This study aims to prevent syndemic health conditions by decreasing acculturative stress and promoting resilience via SER Familia (Salud, Estrés y Resilencia en Familias/ Health, Stress, and Resilience in Families), a…
- Conditions
- Substance Abuse, Intimate Partner Violence (IPV), HIV Infections, Depression
- Trial name
- SER Familia (NCT06627764)
- Testing
- SER Familia
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Duke University
Dengue Fever
Impact of SC vs IM Administration of DENVax (TDV) on Safety and Immunogenicity
This study assessed the safety and immunogenicity of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) previously referred to as DENVax of various dosing schedules via subcutaneous (SC) or intramuscular (IM) administration with…
- Trial name
- NCT01728792
- Testing
- TDV
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Takeda
HIV Infections
Safety of and Immune Response to a New HIV Vaccine: HIV CTL MEP
The effectiveness of a vaccine can be improved by using a "prime boost strategy" or by using an adjuvant. A prime boost strategy is the administration of one type of vaccine (the primer) followed by the administration of another…
- Trial name
- NCT00076037
- Testing
- HIV CTL MEP administered with RC529-SE adjuvant, GM-CSF
- Where
- 7 sites in United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19 Pandemic, COVID-19 Vaccines
UNAIR Inactivated COVID-19 Vaccine as Heterologue Booster (Immunobridging Study)
This is an observer blind randomized controlled trial study to evaluate the humoral immunogenicity profile - neutralizing antibody - after 28 days following vaccination with Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell…
- Trial name
- NCT05918939
- Testing
- Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) 5 µg, CoronaVac Biofarma COVID-1 9 Vaccine 3 µg
- Where
- Indonesia
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Dr. Soetomo General Hospital
Adenovirus
Ad Sensor-based Real-time Diagnosis of Adenovirus
To develop a real-time diagnostic technique with Ad sensor for Adenovirus detection, the investigators conduct a prospective clinical study.
- Trial name
- NCT02008812
- Testing
- Ad sensor
- Where
- Taiwan
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
COVID-19 Pandemic, Simulation of Physical Illness
COVID-19 Simulation Education on Nursing Students
This study aims to determine the effect of simulation education as an approach to patients with COVID-19 on nursing students' perception and fear of the COVID-19 disease.
- Trial name
- NCT05576636
- Testing
- Simulation training, Control Group
- Where
- Turkey (Türkiye)
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Mehmet Akif Ersoy University
HIV Infections
A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of rgp120/HIV-1MN (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults.
PRIMARY: To examine the safety and potential improvement in immune responses elicited by combining rsgp120/HIV-1MN with the adjuvant QS-21.
- Trial name
- NCT00001044
- Testing
- Aluminum hydroxide, QS-21, rgp120/HIV-1MN
- Where
- 4 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Coronavirus Disease 2019 (COVID-19)
Evaluation of Silver Nanoparticles for the Prevention of COVID-19
In this research, silver nanoparticles (AgNPs) were tested in vitro and shown to have an inhibitory effect on SARS-CoV-2 infection in cultured cells.
- Trial name
- COVID-19 (NCT04894409)
- Testing
- Mouthwash and nose rinse with the AgNPs solution, Mouthwashes and nose rinse in a conventional way
- Where
- Mexico
- Volunteers
- 231 people, healthy volunteers welcome
- Sponsor
- Cluster de Bioeconomia de Baja California, A.C
COVID-19
COVID-19 Symptom Tracker
The viral Covid-19 outbreak is now considered a pandemic according to the World Health Organisation (WHO). A free monitoring app 'COVID-19 Symptom Tracker' has been developed to record and monitor the symptoms of the COVID-19…
- Trial name
- NCT04331509
- Testing
- No Intervention
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 10,000,000 people, healthy volunteers welcome
- Sponsor
- King's College London
COVID-19
Clinical Trial to Evaluate the Safety and Immunogenicity of the COVID-19 Vaccine
This is a randomized, placebo-controlled, two center, Phase I trial in healthy adult volunteer participants consisting of two phases, an unblinded dose escalation and a double blind treatment phase to investigate the safety…
- Trial name
- COVID-19-101 (NCT04497298)
- Testing
- Two COVID-19 vaccine candidate (TMV-083/V-591) administrations - Low dose, Two COVID-19 vaccine candidate (TMV-083/V-591) administrations - High dose, One COVID-19 vaccine candidate (TMV-083/V-591) administration - High dose
- Where
- 2 sites in Belgium, France
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Influenza
Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu)
This was a Phase 1/2, randomized, observer-blinded, active-controlled trial to assess the Safety and Tolerability of a Recombinant Trivalent Nanoparticle Influenza Vaccine (Tri-NIV) with Matrix M1™ Adjuvant in Healthy Older…
- Trial name
- NCT03293498
- Testing
- NanoFlu, Fluzone HD - Day 0, Fluzone HD - Day 21
- Where
- 3 sites in United States
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- Novavax
HPV Infection, Cervical Cancer
Effector and Memory Immune Responses to HPV Vaccination in Vietnamese Women Post Virus Exposure
A Study to evaluate if the 3 dose extended schedule (0-6-18 months) for the HPV vaccine Gardasil-9 provide similar immune responses and short term protection against HPV infection compared to the regular 3 dose schedule (0-2-6…
- Conditions
- HPV Infection, Cervical Cancer, Anogenital Cancer, Anogenital Warts
- Trial name
- HPV9vxFSW (NCT06681636)
- Testing
- Human papillomavirus 9-valent vaccine, Recombinant
- Where
- 3 sites in Australia, Vietnam
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- National Institute of Hygiene and Epidemiology, Vietnam
Hepatitis B, Chronic Hepatitis B
Study of the Relative Oral Bioavailability of AL-3778 Tablets and Drug Interaction With Entecavir or Tenofovir Disoproxil Fumarate in Healthy Volunteers
This is an open-label, randomized, multi-part study to evaluate the relative oral bioavailability of a tablet formulation of AL-3778 (formerly NVR 3-778) administered under fasted and fed conditions (Parts 1 and 2) and the…
- Conditions
- Hepatitis B, Chronic Hepatitis B, Viral Hepatitis B
- Trial name
- NCT03032536
- Testing
- AL-3778, Entecavir, Tenofovir disoproxil fumarate
- Where
- 2 sites in New Zealand
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Alios Biopharma Inc.
Influenza, H7N9 Influenza
Safety and Immunogencity of H7N9 Influenza Antigen With 2 Adjuvant Formulations in Healthy Adults in Brazil
The overall aim of this study is to evaluate the safety, immunogenicity and dose sparing effects of H7N9 influenza antigen formulated with 2 different adjuvants .
- Trial name
- NCT03330899
- Testing
- H7N9 antigen + adjuvant IB160, H7N9 antigen + adjuvant SE, H7N9 antigen without adjuvant
- Where
- 3 sites in Brazil
- Volunteers
- 432 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
HIV Infections
A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of MN Recombinant Soluble gp120/HIV-1 (rsgp120/HIV-1) (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults
To extend the evaluation of safety and immunogenicity of MN recombinant soluble gp120/HIV-1 (MN rsgp120/HIV-1) in combination with QS21 with or without alum and on two different vaccination schedules.
- Trial name
- NCT00001052
- Testing
- Aluminum hydroxide, QS-21, rgp120/HIV-1MN
- Where
- 5 sites in United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.